Wednesday, August 30, 2017
Viroclinics, founded in 2001 and specializing in testing new vaccines and drugs in the clinical trial stages prior to their market launch, has been acquired by Parcom Capital. Viroclinics has clients across the globe and conducts virology testing for clients that include the world’s top 10 biopharmaceutical companies. The company is also a market leader in the Netherlands. For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide. The company expects to see further growth in other fields of virology in the coming years.